Background: LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. In a phase 3 randomized, open-label, first-line study in pts with uHCC, LEN demonstrated a treatment effect on overall survival (OS) by statistical confirmation of noninferiority to SOR, with an improved objective response rate.(Kudo et al. Lancet 2018) Preliminary biomarker analyses (n=114) have been presented.(Finn et al. ESMO 2017) We now present the final biomarker analyses and correlations with efficacy for all pts with serum samples (n=407).
No takes yet. Share an insight, caveat, or question.
Finn et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: